Sartorius Stedim Biotech SA (SDMHF) reported a solid first quarter, with net profit rising 3% to €88.1 million and revenues increasing by 2.3% to €761.5 million. The company maintained its fiscal 2026 outlook, projecting sales growth of 6-10% in constant currencies, bolstered by strong demand for biopharma manufacturing consumables. CEO René Fáber expressed confidence in the guidance, anticipating stronger performance in the second half of the year.
The results reflect a resilient business model, with underlying EBITDA up 1.9% to €233.4 million, despite slight pressure on margins due to product mix effects and tariff impacts. The underlying EBITDA margin decreased marginally to 30.7% from 30.8% last year, but the company expects this to improve slightly above 31% moving forward.
For market professionals, Sartorius Stedim’s focus on consumables and stable equipment revenue positions it well for sustained growth, making it a key player to watch in the biopharma sector.
Source: nasdaq.com